Is It Too Late To Consider Royalty Pharma (RPRX) After Strong 57% One Year Rally?

• If you are wondering whether Royalty Pharma’s current share price still makes sense after a strong run, the key is to look closely at what the market might be pricing in.
• The stock last closed at US$49.48, with returns of 1.4% over 7 days, 9.1% over 30 days, 27.3% year to date and 57.4% over the past year, which naturally raises questions about how expectations and risk perceptions are being reflected in the price.
• Recent attention around Royalty Pharma has largely centered on its role as a buyer of biopharma royalties and how that model fits into investors’ search for exposure to healthcare cash flows. News flow has highlighted its portfolio of royalty interests and ongoing activity in acquiring new royalty streams, giving context to why the stock has been on many investors’ radars.
• On Simply Wall St’s 6 point valuation checklist, Royalty Pharma currently scores 2 out of 6. The next sections will walk through what different valuation methods say about that score and then finish with a broader way to think about what the valuation might really mean for you.

Royalty Pharma scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Royalty Pharma Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes expected future cash flows and then discounts them back to today to estimate what the business might be worth right now. It is essentially asking what a rational buyer would pay today for those future cash flows.

For Royalty Pharma, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $341.9 million. Analysts provide explicit free cash flow estimates for the early years, and Simply Wall St then extrapolates further out, with projected free cash flow of $4.3 billion in 2030. These projected cash flows, including the ten year path from 2026 through 2035, are discounted back into today’s dollars using the DCF framework.

On this basis, the DCF model arrives at an estimated intrinsic value of $188.64 per share, compared with the recent share price of $49.48. That gap implies the shares are trading at a 73.8% discount to the model’s estimate of value, which is a wide margin.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Royalty Pharma is undervalued by 73.8%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Royalty Pharma.

Approach 2: Royalty Pharma Price vs Earnings

For profitable companies, the P/E ratio is a useful way to relate what you pay for a share to the earnings that support that price. It gives a quick read on how much investors are willing to pay for each dollar of profit.

What counts as a “normal” or “fair” P/E depends a lot on how the market views a company’s growth potential and risk. Higher expected growth or lower perceived risk can support a higher P/E, while lower growth or higher risk usually leads to a lower multiple.

Royalty Pharma currently trades on a P/E of 28.5x. This sits above both the Pharmaceuticals industry average of 16.2x and the peer average of 20.4x, so the stock is priced at a higher multiple than many sector names. Simply Wall St’s Fair Ratio for Royalty Pharma is 20.1x. This is its proprietary estimate of what the P/E might be given factors such as earnings growth profile, industry, profit margin, market cap and risk characteristics.

The Fair Ratio can be more useful than a simple peer or industry comparison because it adjusts for those company specific factors rather than treating all firms as alike. With Royalty Pharma’s actual P/E of 28.5x above the Fair Ratio of 20.1x, the shares screen as expensive on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Royalty Pharma Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so this is where Narratives come in as a simple way for you to attach a clear story to the numbers behind Royalty Pharma, linking what you believe about its future revenue, earnings and margins to a financial forecast and then to a Fair Value that can be compared with today’s price.

On Simply Wall St’s Community page, Narratives let you choose or create a view that matches your thinking, whether that is closer to the more optimistic fair value of about US$60.61 or the more cautious fair value of US$46.00. You can then see how that stacks up against the recent share price of US$49.48 to help you judge whether the current price looks rich or modest relative to your assumptions.

Because these Narratives are refreshed when new information appears, such as updated guidance, news on deals like the US$250m Zymeworks financing or changes in analyst forecasts, you can quickly see how your preferred Royalty Pharma story translates into updated Fair Value estimates without rebuilding a model from scratch each time.

For Royalty Pharma however we will make it really easy for you with previews of two leading Royalty Pharma Narratives:

🐂 Royalty Pharma Bull Case

Fair value: US$60.61

Upside to this fair value: about 18% above the recent US$49.48 share price

Revenue growth assumption: 22.56% a year

• Assumes Royalty Pharma keeps finding and funding new royalties at attractive terms, helped by its scale, data and long standing industry relationships.
• Builds in analysts’ higher growth view, with revenue and earnings expanding and a P/E of 28.4x on projected 2029 earnings.
• Flags clear risks around drug concentration, regulation, competition for deals and generic or biosimilar pressure on key royalty streams.

🐻 Royalty Pharma Bear Case

Fair value: US$46.00

Downside to this fair value: about 7% below the recent US$49.48 share price

Revenue growth assumption: 16.87% a year

• Builds a cautious case around political and regulatory pressure on drug pricing, weaker intellectual property protection and tougher financing conditions.
• Assumes slower revenue growth and a lower future P/E of 21.6x, while still using the same earnings level that consensus and bullish views reference.
• Accepts that long term sector drivers and partnerships support growth, but questions how much of that is already reflected in the share price.

Taken together, these Narratives give you a clear range for what Royalty Pharma might be worth based on different assumptions about growth, margins, regulation and competition. The key is to decide which story feels closer to how you see the royalty market and Royalty Pharma’s role in it, then check whether the current US$49.48 share price lines up with your chosen view.

See what the community is saying about Royalty Pharma

Do you think there’s more to the story for Royalty Pharma? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com